Business Context and Reporting Period
This Form 8-K Current Report was filed by Frequency Therapeutics, Inc. (trading symbol: FREQ) on March 29, 2023, covering events occurring on March 23, 2023. The company is a Delaware corporation headquartered in Lexington, MA, and its common stock is listed on The Nasdaq Global Select Market.
Key Financial Metrics
This filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial figure disclosed relates to a severance payment of $200,783.81 to a departing executive, representing 100% of his 2023 bonus opportunity.
Material Changes and Events
- Nasdaq Delisting Notice: On March 28, 2023, the company received a notification from Nasdaq stating that its common stock closing bid price had been below the $1.00 minimum requirement for 30 consecutive business days. The company has an initial 180-day compliance period (until September 25, 2023) to regain compliance by maintaining a bid price of at least $1.00 for 10 consecutive business days.
- Executive Departure: Carl LeBel, Ph.D., Chief Development Officer, was terminated effective March 31, 2023, as part of a previously announced reduction in force. A Separation Agreement was executed on March 23, 2023.
Outlook, Risks, and Management Commentary
Compliance Risks: There is no assurance the company will regain compliance with Nasdaq listing requirements. Failure to do so by September 25, 2023, may result in delisting unless the company successfully applies to transfer its listing to The Nasdaq Capital Market, which requires meeting specific market value standards and paying an application fee. An appeal process exists if delisting is finalized, but success is not guaranteed.
Severance Terms: Under the Separation Agreement, Dr. LeBel will receive 12 months of base salary continuation, company-paid COBRA premiums (subject to eligibility), and the aforementioned bonus payment, contingent upon his execution of a general release of claims.
Investor Verification Checklist
- Verify the current trading price of FREQ stock to assess the likelihood of meeting the $1.00 bid price requirement within the 180-day window.
- Review the company's cash position in recent 10-Q or 10-K filings to determine if it can sustain operations and the severance costs during the compliance period.
- Monitor for any subsequent filings regarding a potential transfer application to The Nasdaq Capital Market if the bid price deficiency is not cured by September 2023.
- Confirm the impact of the Chief Development Officer's departure on the company's clinical development pipeline and operational strategy.